MTOR and renal cell carcinoma: Stage IV RCC has been treated successfully with immune therapy and, more recently, with targeted therapies, such as vascular endothelial growth factor (VEGF) receptor–targeted tyrosine kinase inhibitors (TKIs), VEGF antagonists, and mammalian target of rapamycin (mTOR) inhibitors.